Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Merz, Patrick (VerfasserIn) , Ballikaya, Seda (VerfasserIn) , Auffarth, Gerd U. (VerfasserIn) , Schmack, Ingo (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 11 December 2018
In: BMC ophthalmology
Year: 2018, Jahrgang: 18
ISSN:1471-2415
DOI:10.1186/s12886-018-0978-9
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12886-018-0978-9
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12886-018-0978-9
Volltext
Verfasserangaben:Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack
Beschreibung
Zusammenfassung:Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium.
Beschreibung:Gesehen am 21.12.2018
Beschreibung:Online Resource
ISSN:1471-2415
DOI:10.1186/s12886-018-0978-9